N. Finkler

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Anderley Gordon, N. Finkler, Robert P. Edwards et al. · International Journal of Gynecological Cancer · 2005 · 221 citations

Comparison of Serum CA 125, Clinical Impression, and Ultrasound in the Preoperative Evaluation of Ovarian Masses

N. Finkler, Beryl R. Benacerraf, Philip T. Lavin et al. · Journal of diagnostic medical sonography · 1989 · 167 citations

Diagnosis, Gynecology, Surgery +16

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

Ignace Vergote, N. Finkler, J. Del Campo et al. · European Journal of Cancer · 2009 · 102 citations

Medicine, Cancer Management, Gynecology +9

Hemodynamic Evaluation of Angioaccess Procedures for Hemodialysis

Koing Bo Kwun, Harry Schanzer, N. Finkler et al. · Vascular Surgery · 1979 · 75 citations

Hemodialysis, Angioaccess Procedures, Medicine +7

Clinical experience with placental site trophoblastic tumors at the New England Trophoblastic Disease Center.

N. Finkler, Ross S. Berkowitz, S G Driscoll et al. · PubMed · 1988 · 57 citations

Tumoral Pathology, Gynecological Surgery, Prompt Hysterectomy +13